-
肝细胞癌(hepatocellular cancinoma,HCC)是最常见的原发性肝癌之一,其发病率位居所有恶性肿瘤的第6位,病死率位居第4位[1]。我国是HCC大国,每年约有50%的新发病例[2]。巨大HCC(肿瘤长径>5 cm)因肿瘤负荷大导致术后剩余肝脏体积<40%,或因伴有门静脉癌栓导致无法行手术切除。而90Y微球选择性内放射治疗(selective internal radiotherapy,SIRT)具有缩小肿瘤、增大剩余肝脏体积、治疗门静脉癌栓和提高患者生活质量4大优势,成为精准治疗HCC的“核武器”,为患者提供治愈性治疗的机会。
90Y微球在肝细胞癌治疗中的临床应用价值及研究进展
Clinical application value and research progress of 90Y microspheres in the treatment of hepatocellular cancinoma
-
摘要: 肝癌分为原发性肝癌和继发性肝癌两大类。肝细胞癌(HCC)是原发性肝癌中最常见的一种病理类型,其具有发病率高、病死率高的特点。90Y微球选择性内放射治疗(SIRT)可应用于HCC的多个阶段,兼有多重疗效,即可以缩小肿瘤、增大剩余肝脏体积、治疗门静脉癌栓和提高患者的生活质量。笔者介绍了90Y微球SIRT在HCC治疗中的临床应用价值及研究进展。Abstract: Liver cancer can be divided into two categories: primary liver cancer and secondary liver cancer. Hepatocellular cancinoma (HCC) is the most common type of primary liver cancer, which has the characteristics of high incidence and high mortality. 90Y microsphere selective internal radiotherapy (SIRT) can be used in many stages of liver cancer, which can reduce the tumor, increase the volume of the remaining liver, treat portal vein tumor thrombus and improve the quality of life for patients. The clinical application value and research progress of 90Y microspheres SIRT in the treatment of HCC was introduced.
-
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7−33. DOI: 10.3322/caac.21654. [2] Park JW, Chen MS, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9): 2155−2166. DOI: 10.1111/liv.12818. [3] Vogel A, Martinelli E, Vogel A, et al. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines[J]. Ann Oncol, 2021, 32(6): 801−805. DOI: 10.1016/J.ANNONC.2021.02.014. [4] Kim Y, Lee HA, Lee JS, et al. Association between curative treatment after transarterial radioembolization and better survival outcomes in patients with hepatocellular carcinoma[J]. Cancer Invest, 2021, 39(3): 274−283. DOI: 10.1080/07357907.2020.1870126. [5] de Oliveira Carvalho V, Galastri FL, Affonso BB, et al. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports[J]. Einstein (Sao Paulo), 2020, 18: eRC4990. DOI: 10.31744/einstein_journal/2020RC4990. [6] Serenari M, Neri J, Marasco G, et al. Two-stage hepatectomy with radioembolization for bilateral colorectal liver metastases: a case report[J/OL]. World J Hepatol, 2021, 13(2): 261−269[2022-09-29]. https://www.wjgnet.com/1948-5182/full/v13/i2/261.htm. DOI: 10.4254/wjh.v13.i2.261. [7] Bekki Y, Marti J, Toshima T, et al. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma[J]. Surgery, 2021, 169(5): 1044−1051. DOI: 10.1016/J.SURG.2020.12.012. [8] Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis[J]. J Hepatol, 2014, 61(3): 583−588. DOI: 10.1016/j.jhep.2014.04.032. [9] Shui YJ, Yu W, Ren XQ, et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis[J/OL]. Radiat Oncol, 2018, 13(1): 188[2022-09-29]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-018-1136-5. DOI: 10.1186/s13014-018-1136-5. [10] Levi Sandri GB, Ettorre GM, Colasanti M, et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation[J]. Hepatobiliary Surg Nutr, 2017, 6(1): 44−48. DOI: 10.21037/hbsn.2017.01.08. [11] Kim PH, Choi SH, Kim JH, et al. Comparison of radioembolization and Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy[J]. Korean J Radiol, 2019, 20(3): 385−398. DOI: 10.3348/kjr.2018.0496. [12] Pardo F, Sangro B, Lee RC, et al. The post-SIR-spheres surgery study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with Yttrium-90 resin microspheres[J]. Ann Surg Oncol, 2017, 24(9): 2465−2473. DOI: 10.1245/s10434-017-5950-z. [13] Kim HC. Radioembolization for the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23(2): 109−114. DOI: 10.3350/cmh.2017.0004. [14] Cheng SQ, Chen MS, Cai JQ, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)[J]. Liver Cancer, 2020, 9(1): 28−40. DOI: 10.1159/000503685. [15] Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs Sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5): 661−669. DOI: 10.1001/jamaoncol.2017.5847. [16] Park HC, Yu JI, Cheng JCH, et al. Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific primary liver cancer expert meeting (APPLE 2014): current practice and future clinical trials[J]. Liver Cancer, 2016, 5(3): 162−174. DOI: 10.1159/000367766. [17] Somma F, Stoia V, Serra N, et al. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: the impact of portal vein thrombosis on survival[J/OL]. PLoS One, 2019, 14(5): e0216935[2022-09-29]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0216935. DOI: 10.1371/journal.pone.0216935. [18] Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial[J/OL]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1025−1035[2022-09-29]. https://www.sciencedirect.com/science/article/abs/pii/S2468125321003058. DOI: 10.1016/S2468-1253(21)00305-8. [19] Zori AG, Ismael MN, Limaye AR, et al. Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation[J]. Am J Clin Oncol, 2020, 43(5): 325−333. DOI: 10.1097/COC.0000000000000678. [20] Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, Yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma[J/OL]. Adv Radiat Oncol, 2016, 1(1): 35−42[2022-09-29]. https://www.sciencedirect.com/science/article/pii/S2452109415000093. DOI: 10.1016/j.adro.2015.12.003. [21] Sheth RA, Patel MS, Koottappillil B, et al. Role of locoregional therapy and predictors for dropout in patients with hepatocellular carcinoma listed for liver transplantation[J]. J Vasc Interv Radiol, 2015, 26(12): 1761−1768. DOI: 10.1016/j.jvir.2015.08.015. [22] Biederman DM, Titano JJ, Korff RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2018, 29(1): 30−37.e2. DOI: 10.1016/j.jvir.2017.08.026. [23] Padia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study[J]. J Vasc Interv Radiol, 2017, 28(6): 777−785.e1. DOI: 10.1016/j.jvir.2017.02.018. [24] 刘瑞青, 贾中芝, 曹会存, 等. 钇-90微球在治疗手术不可切除且化疗耐药的结直肠癌肝转移中的应用——钇-90微球放射栓塞系列回顾(七)[J]. 介入放射学杂志, 2018, 27(10): 1003−1010. DOI: 10.3969/j.issn.1008-794X.2018.10.023.
Liu RQ, Jia ZZ, Cao HC, et al. The role of Yttrium-90 radioembolization in the treatment of unresectable, chemorefractory colorectal cancer liver metastases. A series review of radioembolization with Yttrium-90 microspheres (part Ⅶ)[J]. J Intervent Radiol, 2018, 27(10): 1003−1010. DOI: 10.3969/j.issn.1008-794X.2018.10.023.
计量
- 文章访问数: 2037
- HTML全文浏览量: 1706
- PDF下载量: 24